Anticancer research最新文献_第4页

Enhancing Estimation Accuracy of Prostate Cancer VMAT Planning: A Knowledge-based Approach Using Multiple Collimator Angles.

IF 1.6 4区医学

Anticancer research Pub Date : 2024-12-01 DOI: 10.21873/anticanres.17358

Tatsuya Kamima, Yoshihiro Ueda, Jun-Ichi Fukunaga, Yumiko Shimizu, Yasuo Yoshioka, Hajime Monzen

{"title":"Enhancing Estimation Accuracy of Prostate Cancer VMAT Planning: A Knowledge-based Approach Using Multiple Collimator Angles.","authors":"Tatsuya Kamima, Yoshihiro Ueda, Jun-Ichi Fukunaga, Yumiko Shimizu, Yasuo Yoshioka, Hajime Monzen","doi":"10.21873/anticanres.17358","DOIUrl":"https://doi.org/10.21873/anticanres.17358","url":null,"abstract":"Background/aim: This study aimed to determine whether a knowledge-based planning model incorporating treatment plans with multiple collimator angles (Multi-coll. model) provides superior estimation accuracy and plan quality for a range of collimator angles compared with a typical institutional model (Inst. model).Materials and methods: Five institutions using volumetric modulated arc therapy for prostate cancer participated in the study. The Inst. model comprised plans using a fixed collimator angle, whereas the Multi-coll. model registered plans using single arcs and collimator angles of 10°, 30°, 50°, and 70°. The coefficient of determination and mean squared error were calculated, and the estimation accuracy and dosimetric results for three validation cases at each institution were compared for each model. Dosimetric parameters included volumes receiving at least 20%, 50%, and 90% of the prescription dose (V20, V50, and V90, respectively) at each collimator angle.Results: The Multi-coll. model yielded a higher coefficient of determination and lower mean squared error than the Inst. model, although overfitting of data was a concern at two institutions. The mean absolute errors between estimated and calculated values were (Inst. model vs. Multi-coll. model): 4.41% vs. 2.60% (V20), 4.03% vs. 2.27% (V50), and 2.07% vs. 1.09% (V90) for the rectum; 3.48% vs. 3.42% (V20), 2.24% vs. 3.65% (V50), and 1.11% vs. 0.73% (V90) for the bladder. The Multi-coll. model exhibited a lower rectal and vesical V20 than the Inst.Model: Conclusion: The Multi-coll. model had a greater estimation accuracy and slightly higher plan quality than the Inst.Model: ","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5303-5312"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imipramine-mediated Suppression of EGFR Signaling Attenuates Invasive and Progressive Abilities of Hepatocellular Carcinoma Cells.

IF 1.6 4区医学

Anticancer research Pub Date : 2024-12-01 DOI: 10.21873/anticanres.17360

Chun-Yu Fu, Pen-An Liao, Tzu-Hsiang Lin, Fei-Ting Hsu, Dai-Cheng Dong, Wei-Ting Chen

{"title":"Imipramine-mediated Suppression of EGFR Signaling Attenuates Invasive and Progressive Abilities of Hepatocellular Carcinoma Cells.","authors":"Chun-Yu Fu, Pen-An Liao, Tzu-Hsiang Lin, Fei-Ting Hsu, Dai-Cheng Dong, Wei-Ting Chen","doi":"10.21873/anticanres.17360","DOIUrl":"https://doi.org/10.21873/anticanres.17360","url":null,"abstract":"Background/aim: Hepatocellular carcinoma (HCC) is a primary liver cancer with high mortality rates worldwide, necessitating effective therapeutic strategies. Imipramine demonstrates the potential to augment standard treatments of different cancers, highlighting its therapeutic promise in oncology. This study aimed to investigate the potential regulation of imipramine on HCC.Materials and methods: Cytotoxicity, apoptosis, metastasis, anti-apoptosis and signaling regulation were assessed in Huh7 and Hep3B cells using MTT assay, flow cytometry, and western blotting.Results: Imipramine markedly induced cytotoxicity and Annexin-V activation in Huh7 and Hep3B cells in a time and dose-dependent manner. Mechanistically, imipramine induced cytotoxicity and apoptosis in HCC cells via both extrinsic (Fas-Fas-L) and intrinsic (mitochondrial) apoptosis pathways. It also suppressed HCC metastasis and inhibited epidermal growth factor receptor (EGFR)/mitogen-activated extracellular signal-regulated kinase (MEK)/extracellular signal-regulated kinases (ERKs) signaling.Conclusion: Imipramine shows promise in enhancing HCC treatment outcomes in patients and targets the EGFR/MEK/ERK signaling pathway in in vitro HCC models, thereby augmenting the effectiveness of standard therapies.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5323-5335"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunohistochemical Expression and Significance of Preferentially Expressed Antigen in Melanoma (PRAME) in Gynecological Tumors: A Single-institution Retrospective Analysis.

IF 1.6 4区医学

Anticancer research Pub Date : 2024-12-01 DOI: 10.21873/anticanres.17377

Yunjoo Cho, Hyun-Soo Kim

{"title":"Immunohistochemical Expression and Significance of Preferentially Expressed Antigen in Melanoma (PRAME) in Gynecological Tumors: A Single-institution Retrospective Analysis.","authors":"Yunjoo Cho, Hyun-Soo Kim","doi":"10.21873/anticanres.17377","DOIUrl":"https://doi.org/10.21873/anticanres.17377","url":null,"abstract":"Background/aim: Although preferentially expressed antigen in melanoma (PRAME) has been used as a diagnostic marker for malignant melanoma (MM), it is also expressed in various other malignancies. PRAME expression is rarely reported in female genital tumors. This study aimed to evaluate PRAME expression and its significance in gynecological malignancies.Patients and methods: We conducted PRAME immunostaining in 135 specimens, including 85 endometrial carcinomas (ECs), five uterine sarcomas (USs), 28 cervical carcinomas (CCs), and 17 ovarian carcinomas (OCs). PRAME immunoreactivity was evaluated using a semi-quantitative histoscore method.Results: PRAME was expressed in 82 (96.5%) ECs, 15 (88.2%) OCs, three (60.0%) USs, and eight (28.6%) CCs, with mean histoscores of 174.6, 108.9, 32.2, and 27.5, respectively. EC exhibited elevated PRAME expression levels compared to other tumors, with immunoreactivity being higher in endometrial endometrioid carcinoma (EEC) than that in other EC types. Grade 1 EEC exhibited higher PRAME expression levels than grade 2-3 EECs.Conclusion: PRAME over-expression in gynecological tumors supports the notion that this marker should not be regarded as specific to MM alone. EC exhibited higher PRAME expression than CC and OC, and low-grade EEC displayed higher PRAME immunoreactivity than other EC types. Our findings suggest that PRAME immunostaining can be useful to distinguish EEC from ovarian endometrioid carcinoma and endocervical adenocarcinoma. PRAME over-expression can also help differentiate non-aggressive EC from aggressive EC.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5515-5524"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synergistic Effects of Inecalcitol With Imatinib and Dasatinib on Chronic Myeloid Leukemia Cell Lines.

IF 1.6 4区医学

Anticancer research Pub Date : 2024-12-01 DOI: 10.21873/anticanres.17345

Samuel Angel, Emma Cowles, Jeams Costa, Raad Al Ani, Kallidaikurichi V Venkatachalam

{"title":"Synergistic Effects of Inecalcitol With Imatinib and Dasatinib on Chronic Myeloid Leukemia Cell Lines.","authors":"Samuel Angel, Emma Cowles, Jeams Costa, Raad Al Ani, Kallidaikurichi V Venkatachalam","doi":"10.21873/anticanres.17345","DOIUrl":"https://doi.org/10.21873/anticanres.17345","url":null,"abstract":"Background/aim: According to American Cancer Society's recent estimates, about 5,330 men and 3,950 women are diagnosed each year with chronic myeloid leukemia (CML). Roughly, 750 men and 530 women are predicted to die as a result of CML, establishing a dire need for advancements in CML treatment. Tyrosine kinase inhibitors (TKIs) imatinib and dasatinib have profound effects for prognosis and delaying survival from CML. The role of inecalcitol in the treatment and prevention of various cancers including leukemia has been established. The aim of this study was to analyze the putative synergistic treatment effects of inecalcitol in combination with imatinib or dasatinib on various cell lines including AR-230, LAMA-84-s, KCL-22, and U-937.Materials and methods: Cells grown in plates were treated alone or with varying combinations of inecalcitol, imatinib, and dasatinib and incubated for 48 h at 37°C. Cell death was determined using MTT assay.Results: KCL-22 and U-937 were resistant to both combination treatments, whereas AR-230 exhibited a maximal antiproliferative effect (24%) with the combined treatment of imatinib (0.325 μM) and inecalcitol (15.8 μM) (p<0.001). With dasatinib (0.456 nM) and inecalcitol (15.8 μM), AR-230 exhibited a 34% antiproliferative effect (p<0.001). In drastic contrast, LAMA84-s exhibited a 45% antiproliferative effect (with the combined treatment of imatinib (0.325 μM) and inecalcitol (15.8 μM) (p<0.006). Notably, with dasatinib (0.456 nM) and inecalcitol (15.8 μM), LAMA84-s exhibited approximately 78% cell killing (p<0.007).Conclusion: The study suggests that the synergistic effects of inecalcitol with imatinib on cell killing are more drastic in some cells than others. These varying effects may be due to differences in cell metabolism.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5193-5197"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Plasma Metagenomic Next-generation Sequencing and PCR Methods for Epstein-Barr Virus Viral Load Monitoring in Nasopharyngeal Carcinoma.

IF 1.6 4区医学

Anticancer research Pub Date : 2024-12-01 DOI: 10.21873/anticanres.17370

Harish N Vasudevan, Ann A Lazar, Kevin Reyes, D A Rong, Shaun Arevalo, Scot Federman, Jason W Chan, Charles Y Chiu, Steve Miller, Sue S Yom

{"title":"Comparison of Plasma Metagenomic Next-generation Sequencing and PCR Methods for Epstein-Barr Virus Viral Load Monitoring in Nasopharyngeal Carcinoma.","authors":"Harish N Vasudevan, Ann A Lazar, Kevin Reyes, D A Rong, Shaun Arevalo, Scot Federman, Jason W Chan, Charles Y Chiu, Steve Miller, Sue S Yom","doi":"10.21873/anticanres.17370","DOIUrl":"https://doi.org/10.21873/anticanres.17370","url":null,"abstract":"Background/aim: Plasma Epstein-Barr virus (EBV) viral load measurement is prognostic in nasopharyngeal carcinoma (NPC) disease monitoring; however, a consensus measurement approach does not exist. This study characterized the clinical performance of metagenomic next-generation sequencing (mNGS), an unbiased sequencing-based assay distinct from polymerase chain reaction (PCR) or targeted sequencing approaches, in 73 peripheral blood specimens from 32 patients diagnosed with NPC.Patients and methods: Samples were analyzed for plasma EBV viral load either by mNGS profiling or PCR-based assays (either LMP2 or BAMHI-W PCR) and compared to tumor presence by clinical assessment. Plasma mNGS-based EBV detection was quantified as reads per million (RPM).Results: Plasma mNGS displayed similar overall performance (100% sensitivity, 86% specificity, 92% accuracy) to BAMHI-W PCR (100% sensitivity, 86% specificity, 94% accuracy) and superior performance to the LMP2 PCR assay (36% sensitivity, 56% specificity, 45% accuracy). In a subset of 13 patients who underwent longitudinal analysis, plasma mNGS EBV RPM correlated with cancer recurrence (95%CI Pre-CRT=232.10±214; 95%CI Post-CRT=0.34±0.32; 95%CI difference=-231.70±214; *p=0.03, paired t-test), suggesting plasma mNGS exhibits potential for monitoring recurrence.Conclusion: Plasma mNGS is a distinct method for EBV titer measurement in NPC patients and more broadly, is a promising method for non-invasive monitoring of disease status for infection-associated malignancies.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5445-5453"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Novel Oncolytic Viral Therapy Using Coxsackievirus B3 (CVB3) for Human Pancreatic Cancer Including Cancer-associated Fibroblasts.

IF 1.6 4区医学

Anticancer research Pub Date : 2024-12-01 DOI: 10.21873/anticanres.17348

Hisanobu Ogata, Akira Imaizumi, Yutaka Fujioka, Hiroyuki Shimizu, Yusuke Hirata, Atsushi Matsuzawa, Toshihisa Tsuruta, Hiroaki Niiro, Hideya Onishi, Masafumi Nakamura, Kenzaburo Tani

{"title":"A Novel Oncolytic Viral Therapy Using Coxsackievirus B3 (CVB3) for Human Pancreatic Cancer Including Cancer-associated Fibroblasts.","authors":"Hisanobu Ogata, Akira Imaizumi, Yutaka Fujioka, Hiroyuki Shimizu, Yusuke Hirata, Atsushi Matsuzawa, Toshihisa Tsuruta, Hiroaki Niiro, Hideya Onishi, Masafumi Nakamura, Kenzaburo Tani","doi":"10.21873/anticanres.17348","DOIUrl":"https://doi.org/10.21873/anticanres.17348","url":null,"abstract":"Background/aim: Pancreatic cancer is a major cause of mortality in the world. It is one of most aggressive diseases, with a 5-year survival rate of <10%. Cancer associated fibroblasts (CAFs) are the predominant non-cancer cells in pancreatic cancer tissues, playing a critical role in modulating the extracellular matrix (ECM). The ECM, maintained by CAFs, significantly impacts the sensitivity of cancer cells to anti-cancer drugs, contributing to tumor progression and resistance to both chemotherapy and immunotherapy. Therefore, targeting CAFs and the ECM may enhance the effectiveness of therapies like FOLFIRINOX. This study aimed to develop a novel oncolytic virotherapy for treatment-resistant pancreatic cancer.Materials and methods: In the first screening assay, we found that coxsackievirus B3 (CVB3) exhibited potent oncolytic activity. We examined whether CVB3 has oncolytic effects on human pancreatic cancer cells in vitro, and whether it has oncolytic activity against cancer-associated fibroblasts (CAFs) in pancreatic cancer.Results: CVB3 demonstrated potent oncolytic effects in two out of three pancreatic cancer cell lines tested. Additionally, CVB3 demonstrated a cell-killing effect on CAFs, indicating its dual activity against both pancreatic cancer cells and the supportive stromal environment.Conclusion: CVB3 shows promise as an oncolytic virus effective against pancreatic cancer cells and CAFs, suggesting its potential as a novel virotherapy for pancreatic cancer. These findings highlight CVB3 as a candidate for further development as a therapeutic modality aimed at improving drug sensitivity and patient prognosis in pancreatic cancer.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5215-5218"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exposure to Hypoxic Conditions Up-regulates HER2 in Breast Cancer Cell Lines.

IF 1.6 4区医学

Anticancer research Pub Date : 2024-12-01 DOI: 10.21873/anticanres.17344

Nobuyasu Suganuma, Nao Saito, Mio Yasukawa, Takashi Yamanaka, Toshinari Yamashita, Yohei Miyagi, Aya Saito, Daisuke Hoshino

{"title":"Exposure to Hypoxic Conditions Up-regulates HER2 in Breast Cancer Cell Lines.","authors":"Nobuyasu Suganuma, Nao Saito, Mio Yasukawa, Takashi Yamanaka, Toshinari Yamashita, Yohei Miyagi, Aya Saito, Daisuke Hoshino","doi":"10.21873/anticanres.17344","DOIUrl":"https://doi.org/10.21873/anticanres.17344","url":null,"abstract":"Background/aim: Tissue specimen quality is becoming increasingly important for basic research and routine clinical results. Warm ischemia time (WIT) affects human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) scores. However, the role of WIT on HER2 modulation remains unclear. We hypothesized that the WIT-mediated increase in HER2 IHC scores was caused by hypoxia. Therefore, this study aimed to determine the mechanism by which WIT mediates the increase in HER2.Materials and methods: HER2 mRNA expression was measured in 4T1, SKBR3, and HCC1954 breast cancer cell lines using real-time PCR following hypoxia exposure. The membrane proteins were isolated and extracted using the Mem-PER™ Plus Membrane Protein Extraction Kit (Thermo Fisher Scientific, Waltham, MA, USA) or evaluated through non-permeabilized immunofluorescent analysis.Results: Hypoxic conditions up-regulated GLUT1 mRNA expression but not HER2 expression. The HER2 membrane protein fraction increased in response to hypoxic conditions. Nonpermeabilized immunofluorescence analysis showed that membrane-bound HER2 was also promoted under hypoxic conditions.Conclusion: HER2 is not regulated at the mRNA level; however, the level of membrane-bound HER2 increases in response to hypoxia.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5187-5192"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GNAO1: A Novel Tumor Suppressor Gene in Colorectal Cancer Pathogenesis.

IF 1.6 4区医学

Anticancer research Pub Date : 2024-12-01 DOI: 10.21873/anticanres.17368

Hong-Beum Kim, Woo Young Choi, Seong-Hun Kim, Hee-Jeong Lee, Sang-Gon Park

引用次数: 0

Survival Outcomes and Disparities in Surgery Refusal for Papillary Thyroid Cancer.

IF 1.6 4区医学

Anticancer research Pub Date : 2024-12-01 DOI: 10.21873/anticanres.17371

Jade C Bowers, Bansi P Savaliya, Swathi R Raikot, Syeda Hoorulain Ahmed, Ramin Shekouhi, Reed Popp, Kyle Popp, Kulkaew B Sukniam, Gabrielle Kowkabany, Paola Berrios Jimenez, Fatima Mubarak, Esinam P Ekpeh, Shivam Bansal, Seema Sharan, Harsheen K Manaise, Emmanuel M Gabriel

{"title":"Survival Outcomes and Disparities in Surgery Refusal for Papillary Thyroid Cancer.","authors":"Jade C Bowers, Bansi P Savaliya, Swathi R Raikot, Syeda Hoorulain Ahmed, Ramin Shekouhi, Reed Popp, Kyle Popp, Kulkaew B Sukniam, Gabrielle Kowkabany, Paola Berrios Jimenez, Fatima Mubarak, Esinam P Ekpeh, Shivam Bansal, Seema Sharan, Harsheen K Manaise, Emmanuel M Gabriel","doi":"10.21873/anticanres.17371","DOIUrl":"https://doi.org/10.21873/anticanres.17371","url":null,"abstract":"Background/aim: Surgery is the cornerstone of treatment for papillary thyroid cancer (PTC), yet some patients refuse surgery, which may impact their survival outcomes. Understanding factors associated with surgery refusal could inform interventions to improve acceptance of recommended care.Patients and methods: This retrospective cohort study evaluated the impact of surgery refusal on overall survival (OS) and identified associated demographic and clinical factors using data on patients with PTC from the National Cancer Database from 2004 to 2019. OS was analyzed using the Kaplan-Meier method, with survival curves compared using the log-rank test. Patient characteristics were analyzed using Pearson Chi-square tests or Wilcoxon Rank Sum tests.Results: Of the 201,051 patients with PTC who were advised to undergo surgery, 200,656 (99.8%) underwent surgery, while 395 (0.2%) refused. Patients who refused surgery were older (mean age 55.2 years vs. 48.7 years), more often male (27.8% vs. 22.8%), and represented higher proportions of Black, Asian, Hispanic, lower-income, uninsured, and non-privately insured patients (p<0.001). OS rates were significantly lower in patients who refused surgery, with one-year and five-year survival rates of 87% and 34%, respectively, compared to 96% and 56% for those who underwent surgery.Conclusion: Surgery refusal in patients with PTC was associated with poorer OS outcomes and was more frequent among older adults, socioeconomically disadvantaged populations, and racial and ethnic minorities. Interventions addressing patient concerns and barriers to surgery are critical to improving treatment acceptance and survival among these groups.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5455-5461"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association Between PD-L1 Expression and Efficacy of Chemoimmunotherapy in Extensive-stage Small Cell Lung Cancer.

IF 1.6 4区医学

Anticancer research Pub Date : 2024-12-01 DOI: 10.21873/anticanres.17379

Kenjiro Tsuruoka, Yosuke Tamura, Yasuyuki Shimazu, Masahiro Arai, Sho Mitsuya, Tomoya Funamoto, Hiroyuki Tsuji, Ninso Matsunaga, Takahiko Nakamura, Soichiro Ikeda, Shigeru Kawabata, Akihisa Imagawa, Yasuhito Fujisaka

{"title":"Association Between PD-L1 Expression and Efficacy of Chemoimmunotherapy in Extensive-stage Small Cell Lung Cancer.","authors":"Kenjiro Tsuruoka, Yosuke Tamura, Yasuyuki Shimazu, Masahiro Arai, Sho Mitsuya, Tomoya Funamoto, Hiroyuki Tsuji, Ninso Matsunaga, Takahiko Nakamura, Soichiro Ikeda, Shigeru Kawabata, Akihisa Imagawa, Yasuhito Fujisaka","doi":"10.21873/anticanres.17379","DOIUrl":"https://doi.org/10.21873/anticanres.17379","url":null,"abstract":"Background/aim: Few studies have examined the association between programmed cell death ligand 1 (PD-L1) expression in small cell lung cancer and the effect of chemoimmunotherapy.Patients and methods: Patients diagnosed with extensive-stage small cell lung cancer at our hospital between September 2019 and August 2023, who were treated with atezolizumab plus carboplatin and etoposide and had pathological tissue immunostained with SP142, were retrospectively examined to determine whether treatment efficacy differed depending on the expression of PD-L1.Results: Twenty-nine patients were analyzed. SP142 immunostaining revealed that the tumor cell (TC) score was 3, 2, 1, and 0 in 1, 0, 0, and 28 cases, respectively. The tumor-infiltrating cell (IC) score was 3, 2, 1, and 0 in 1, 0, 5, and 23 cases, respectively. The median progression-free survival (PFS) of the patients who tested positive and negative for TC was 13 and 5 months, respectively [hazard ratio (HR)=0.041; 95% confidence interval (CI)=0.000-36.225; p=0.109]; and the median overall survival (OS) was 13 and 7.5 months (HR=0.046; 95%CI=0.000-948.833; p=0.338), respectively. The median PFS of the patients who tested positive and negative for IC was 8 and 4 months, respectively (HR=0.216; 95%CI=0.061-0.765; p=0.004); the median OS was 15 and 8 months, respectively (HR=0.573; 95%CI=0.168-1.955; p=0.346).Conclusion: Patients who tested positive for IC had a significantly longer PFS than those who tested negative. Thus, PD-L1 expression may be a predictive factor of efficacy of chemoimmunotherapy in extensive-stage small cell lung cancer.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5531-5539"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0